Published in Dig Dis Sci on October 01, 2002
Hepatic safety of antibiotics used in primary care. J Antimicrob Chemother (2011) 1.07
Clinical and histologic features of azithromycin-induced liver injury. Clin Gastroenterol Hepatol (2014) 0.89
A case of prolonged cholestatic hepatitis induced by azithromycin in a young woman. Case Reports Hepatol (2012) 0.86
A case of acute hepatitis with Mycoplasma pneumoniae infection and transient depression of multiple coagulation factors. Yonsei Med J (2008) 0.79
Azithromycin induced hepatocellular toxicity and hepatic encephalopathy in asymptomatic dilated cardiomyopathy. Indian J Pharmacol (2011) 0.75
Pharmacokinetic and in vivo studies with azithromycin (CP-62,993), a new macrolide with an extended half-life and excellent tissue distribution. Antimicrob Agents Chemother (1987) 3.49
Comparative tolerability of erythromycin and newer macrolide antibacterials in paediatric patients. Drug Saf (1999) 1.17
Erythromycin-associated cholestatic hepatitis. Med J Aust (1993) 0.94
Antibacterial-induced hepatotoxicity. Incidence, prevention and management. Drug Saf (1996) 0.94
Hepatotoxicity of erythromycin. J Infect Dis (1969) 0.94
Azithromycin for treatment of community acquired pneumonia caused by Legionella pneumophila: a retrospective study. Scand J Infect Dis (1995) 0.83
Azithromycin-induced intrahepatic cholestasis. Am J Med (1997) 0.83
Hypersensitivity syndrome associated with azithromycin. Am J Med (2001) 0.78
Fulminant hepatic failure associated with intravenous erythromycin lactobionate. Arch Intern Med (1990) 0.75
Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. Hepatology (2004) 6.98
A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells. Nat Med (2006) 6.31
Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection. J Heart Lung Transplant (2005) 5.87
Antibody-mediated rejection criteria - an addition to the Banff 97 classification of renal allograft rejection. Am J Transplant (2003) 4.54
Tolerogenic immunosuppression for organ transplantation. Lancet (2003) 4.09
All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology (2015) 3.96
Production of alpha 1,3-galactosyltransferase-deficient pigs. Science (2002) 3.96
Progressive fibrosis in nonalcoholic steatohepatitis: association with altered regeneration and a ductular reaction. Gastroenterology (2007) 3.18
Transcriptomic and genomic analysis of human hepatocellular carcinomas and hepatoblastomas. Hepatology (2006) 2.08
A prospective randomized trial of mycophenolate mofetil in liver transplant recipients with hepatitis C. Liver Transpl (2002) 2.07
Kidney transplantation under minimal immunosuppression after pretransplant lymphoid depletion with Thymoglobulin or Campath. J Am Coll Surg (2005) 1.93
Evidence for hyperacute rejection of human liver grafts: The case of the canary kidneys. Clin Transplant (1989) 1.74
Surgically-induced weight loss significantly improves nonalcoholic fatty liver disease and the metabolic syndrome. Ann Surg (2005) 1.70
Risk for depression during interferon-alpha treatment is affected by the serotonin transporter polymorphism. Biol Psychiatry (2008) 1.66
Immunosuppression for liver transplantation in HCV-infected patients: mechanism-based principles. Liver Transpl (2005) 1.61
A repertoire-independent and cell-intrinsic defect in murine GVHD induction by effector memory T cells. Blood (2011) 1.60
Memory T cells from minor histocompatibility antigen-vaccinated and virus-immune donors improve GVL and immune reconstitution. Blood (2011) 1.55
ERBB-2 overexpression and cyclooxygenase-2 up-regulation in human cholangiocarcinoma and risk conditions. Hepatology (2002) 1.54
Kidney transplantation under a tolerogenic regimen of recipient pretreatment and low-dose postoperative immunosuppression with subsequent weaning. Ann Surg (2003) 1.52
Enhancing alloreactivity does not restore GVHD induction but augments skin graft rejection by CD4⁺ effector memory T cells. Eur J Immunol (2011) 1.49
Acute antibody-mediated rejection of cardiac transplants. J Heart Lung Transplant (2006) 1.48
Use of alemtuzumab and tacrolimus monotherapy for cadaveric liver transplantation: with particular reference to hepatitis C virus. Transplantation (2004) 1.43
MELD and prediction of post-liver transplantation survival. Liver Transpl (2006) 1.33
Complete immunosuppression withdrawal and subsequent allograft function among pediatric recipients of parental living donor liver transplants. JAMA (2012) 1.33
Expression of specific hepatocyte and cholangiocyte transcription factors in human liver disease and embryonic development. Lab Invest (2008) 1.32
Cytokine-induced depression during IFN-alpha treatment: the role of IL-6 and sleep quality. Brain Behav Immun (2009) 1.31
Upper-extremity transplantation using a cell-based protocol to minimize immunosuppression. Ann Surg (2013) 1.30
Liver disease selectively modulates cytochrome P450--mediated metabolism. Clin Pharmacol Ther (2006) 1.29
Wnt'er in liver: expression of Wnt and frizzled genes in mouse. Hepatology (2007) 1.27
Effects of donor T-cell trafficking and priming site on graft-versus-host disease induction by naive and memory phenotype CD4 T cells. Blood (2008) 1.27
Liver biopsy interpretation for causes of late liver allograft dysfunction. Hepatology (2006) 1.24
Cyclooxygenase-2-derived prostaglandin E2 activates beta-catenin in human cholangiocarcinoma cells: evidence for inhibition of these signaling pathways by omega 3 polyunsaturated fatty acids. Cancer Res (2008) 1.16
Depression following pegylated interferon-alpha: characteristics and vulnerability. J Psychosom Res (2007) 1.16
Detecting cholangiocarcinoma in patients with primary sclerosing cholangitis. Gastrointest Endosc (2002) 1.16
Histologic graft assessment after clinical islet transplantation. Transplantation (2009) 1.12
NK cells delay allograft rejection in lymphopenic hosts by downregulating the homeostatic proliferation of CD8+ T cells. J Immunol (2010) 1.09
Liver biopsy findings from healthy potential living liver donors: reasons for disqualification, silent diseases and correlation with liver injury tests. J Hepatol (2008) 1.08
Genotyping of hepatocellular carcinoma in liver transplant recipients adds predictive power for determining recurrence-free survival. Liver Transpl (2003) 1.08
Serum analysis after transplant nephrectomy reveals restricted antibody specificity patterns against structurally defined HLA class I mismatches. Transpl Immunol (2005) 1.05
Graft-versus-host disease is independent of innate signaling pathways triggered by pathogens in host hematopoietic cells. J Immunol (2010) 1.04
Gut-derived commensal bacterial products inhibit liver dendritic cell maturation by stimulating hepatic interleukin-6/signal transducer and activator of transcription 3 activity. Hepatology (2007) 1.03
Microdissection-based allelotyping discriminates de novo tumor from intrahepatic spread in hepatocellular carcinoma. Hepatology (2003) 1.03
Liver transplantation for severe intrahepatic noncirrhotic portal hypertension. Liver Transpl (2005) 1.02
Long-term effects of alemtuzumab on regulatory and memory T-cell subsets in kidney transplantation. Transplantation (2012) 1.01
Langerhans cells are not required for graft-versus-host disease. Blood (2010) 1.01
Poor sleep quality predicts onset of either major depression or subsyndromal depression with irritability during interferon-alpha treatment. Psychiatry Res (2010) 1.01
Diffuse desmoplastic metastatic breast cancer simulating cirrhosis with severe portal hypertension: a case of "pseudocirrhosis". Dig Dis Sci (2007) 1.01
Small proline-rich proteins 2 are noncoordinately upregulated by IL-6/STAT3 signaling after bile duct ligation. Lab Invest (2005) 1.00
Preexisting epithelial diversity in normal human livers: a tissue-tethered cytometric analysis in portal/periportal epithelial cells. Hepatology (2013) 0.99
Labile anger during interferon alfa treatment is associated with a polymorphism in tumor necrosis factor alpha. Clin Neuropharmacol (2010) 0.97
Growth factor-induced mobilization of dendritic cells in kidney and liver of rhesus macaques: implications for transplantation. Transplantation (2007) 0.95
Profound depletion of host conventional dendritic cells, plasmacytoid dendritic cells, and B cells does not prevent graft-versus-host disease induction. J Immunol (2012) 0.95
Lessons of organ-induced tolerance learned from historical clinical experience. Transplantation (2004) 0.94
Caroli's disease and orthotopic liver transplantation. Liver Transpl (2006) 0.92
Hepatic B7 homolog 1 expression is essential for controlling cold ischemia/reperfusion injury after mouse liver transplantation. Hepatology (2011) 0.91
Bariatric surgery-induced weight loss reduces hepatic lipid peroxidation levels and affects hepatic cytochrome P-450 protein content. Ann Surg (2010) 0.91
Memory T cells migrate to and reject vascularized cardiac allografts independent of the chemokine receptor CXCR3. Transplantation (2011) 0.91
An inhibitor of cyclin-dependent kinase, stress-induced p21Waf-1/Cip-1, mediates hepatocyte mito-inhibition during the evolution of cirrhosis. Hepatology (2005) 0.90
Gut bacteria drive Kupffer cell expansion via MAMP-mediated ICAM-1 induction on sinusoidal endothelium and influence preservation-reperfusion injury after orthotopic liver transplantation. Am J Pathol (2012) 0.90
Regulation and function of trefoil factor family 3 expression in the biliary tree. Am J Pathol (2004) 0.90
Webcasting pathology department conferences in a geographically distributed medical center. Hum Pathol (2004) 0.89
Four-color flow cytometric analysis of peripheral blood donor cell chimerism. Hum Immunol (2003) 0.89
Roles of dendritic cells in murine hepatic warm and liver transplantation-induced cold ischemia/reperfusion injury. Hepatology (2013) 0.89
Heterotopic breast epithelial inclusion of the heart: report of a case. Am J Surg Pathol (2010) 0.88
Recipient B cells are not required for graft-versus-host disease induction. Biol Blood Marrow Transplant (2010) 0.88
Cooperation of p300 and PCAF in the control of microRNA 200c/141 transcription and epithelial characteristics. PLoS One (2012) 0.88
IL28B polymorphism is associated with both side effects and clearance of hepatitis C during interferon-alpha therapy. J Interferon Cytokine Res (2010) 0.88
Portacaval shunt causes apoptosis and liver atrophy in rats despite increases in endogenous levels of major hepatic growth factors. J Hepatol (2002) 0.88
Histopathologic characteristics of human intestine allograft acute rejection in patients pretreated with thymoglobulin or alemtuzumab. Am J Gastroenterol (2006) 0.88
Liver transplantation in precirrhotic biliary tract disease: Portal hypertension is frequently associated with nodular regenerative hyperplasia and obliterative portal venopathy. Am J Surg Pathol (2006) 0.88
Sofosbuvir With Velpatasvir in Treatment-Naive Noncirrhotic Patients With Genotype 1 to 6 Hepatitis C Virus Infection: A Randomized Trial. Ann Intern Med (2015) 0.87
3D-confocal structural analysis of bone marrow-derived renal tubular cells during renal ischemia/reperfusion injury. Lab Invest (2006) 0.86
Antibody-mediated rejection as a contributor to previously unexplained early liver allograft loss. Liver Transpl (2014) 0.85
Small proline rich protein 2a in benign and malignant liver disease. Hepatology (2014) 0.85
Histologic abnormalities are common in protocol liver allograft biopsies from patients with normal liver function tests. Am J Surg Pathol (2008) 0.85
Estrogen stimulates female biliary epithelial cell interleukin-6 expression in mice and humans. Hepatology (2010) 0.84
Five cases of fulminant hepatitis due to herpes simplex virus in adults. Dig Dis Sci (2002) 0.84
Exogenous IL-6 inhibits acute inflammatory responses and prevents ischemia/reperfusion injury after intestinal transplantation. Am J Transplant (2004) 0.84
Plasma cell hepatitis in liver allografts: Variant of rejection or autoimmune hepatitis? Liver Transpl (2008) 0.83
Sofosbuvir Plus Velpatasvir Combination Therapy for Treatment-Experienced Patients With Genotype 1 or 3 Hepatitis C Virus Infection: A Randomized Trial. Ann Intern Med (2015) 0.83
Racial differences in response rates to consensus interferon in HCV infected patients naive to previous therapy. J Clin Gastroenterol (2004) 0.83
Minimal evidence of transdifferentiation from recipient bone marrow to parenchymal cells in regenerating and long-surviving human allografts. Am J Transplant (2003) 0.83
Simultaneous bone marrow and intestine transplantation promotes marrow-derived hematopoietic stem cell engraftment and chimerism. Blood (2006) 0.82
Memory T cells in GVHD and GVL. Biol Blood Marrow Transplant (2008) 0.82
Progression of liver fibrosis in patients with chronic hepatitis C after orthotopic liver transplantation. Transplantation (2003) 0.82
Impact of anti-hepatitis Bc-positive grafts on the outcome of liver transplantation for HBV-related cirrhosis. Transplantation (2002) 0.82
Acute cholestatic hepatitis associated with long-term use of rofecoxib. Dig Dis Sci (2004) 0.82
Early passenger leukocyte migration and acute immune reactions in the rat recipient spleen during liver engraftment: with particular emphasis on donor major histocompatibility complex class II+ cells. Transplantation (2002) 0.81
Posttransplant adenoviral enteropathy in patients with small bowel transplantation. Arch Pathol Lab Med (2008) 0.80
Clonorchis sinensis-associated cholangiocarcinoma: a case report and review of the literature. Dig Dis Sci (2005) 0.80
HLA matching and the point system. Clin Transplant (1993) 0.80
CTLA4-Ig-based conditioning regimen to induce tolerance to cardiac allografts. J Surg Res (2006) 0.79
A clinicopathologic study of isolated intestinal allografts with preformed IgG lymphocytotoxic antibodies. Hum Pathol (2004) 0.79
SPRR2A expression in cholangiocarcinoma increases local tumor invasiveness but prevents metastasis. Clin Exp Metastasis (2013) 0.79
Suprahepatic Budd-Chiari syndrome treated with thrombectomy and cavoplasty. Dig Dis Sci (2003) 0.79
De novo malignancies after intestinal and multivisceral transplantation. Transplantation (2004) 0.79
Chimerism and tolerance in rat recipients of intestinal allografts from ALS-treated donors with and without adjunct naïve-donor-strain bone-marrow cells. Transplantation (2003) 0.79